Strategies for the synthesis of the novel antitumor agent peloruside A

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 2, 2008, Pages 251-271

  Williams, David R ^a   Nag, Partha P ^a   Zorn, Nicolas ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

(+) peloruside A; Anticancer drug; Antitumor agent; Asymmetric synthesis; Marine macrolide; Microtubule stabilizer; Total synthesis

Indexed keywords

ANTINEOPLASTIC AGENT; BRYOSTATIN; LAULIMALIDE; MYCALAMIDE A; NATURAL PRODUCT; PACLITAXEL; PATEAMINE; PELORUSIDE A; UNCLASSIFIED DRUG;

CHIRALITY; DRUG CONFORMATION; DRUG ISOLATION; DRUG SYNTHESIS; HUMAN; MOLECULAR MODEL; REVIEW; RING CLOSING METATHESIS; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BICYCLO COMPOUNDS, HETEROCYCLIC; HUMANS; INDICATORS AND REAGENTS; LACTONES; MODELS, MOLECULAR; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 39549103093     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Newman DJ, Cragg GM: Natural products as sources of new drugs over the last 25 years. J Nat Prod (2007) 70(3):461-477. •• Provides an excellent review that summarizes the approved agents for treatment of all diseases worldwide for the last 25 years and all antitumor drugs for the last 50 years.
2. Altmann K-H, Gertsch J: Anticancer drugs from nature - Natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep (2007) 24(2):327-357. • Documents the increasing importance of marine metabolites as sources of potential drugs for cancer chemotherapy.
3. Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH: Marine natural products as anticancer drugs. Mol Cancer Ther (2005) 4(2):333-342. •• Discusses several marine natural products and their synthetic derivatives as potential anticancer drugs.
4. West LM, Northcote PT, Battershill CN: Peloruside A: A potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J Org Chem (2000) 65(2):445-449. •• Describes the isolation and structural determination of peloruside A.
5. Page M, West L, Northcote P, Battershill C, Kelly M: Spatial and temporal variability of cytotoxic metabolites in populations of the New Zealand sponge Mycale hentscheli. J Chem Ecol (2005) 31(5):1161-1174.
6. Page MJ, Northcote PT, Webb VL, Mackey S, Handley SJ: Aquaculture trials for the production of biologically active metabolites in the New Zealand sponge Mycale hentscheli (Demospongiae: Poecilosclerida). Aquaculture (2005) 250(1-2):256-269.
7. Hale KJ, Hummersone MG, Manaviazar S, Frigerio M: The chemistry and biology of the bryostatin antitumour macrolides. Nat Prod Rep (2002) 19(4):413-453.
8. Wender PA, DeBrabander J, Harran PG, Jimenez J-M, Koehler MFT, Lippa B, Park C-M, Siedenbiedel C, Pettit GR: The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1. Proc Natl Acad Sci USA (1998) 95(12):6624-6629.
9. Hood KA, Bäckström BT, West LM, Northcote PT, Berridge MV, Miller JH: The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin 1, has unique bioactivity independent of protein kinase C. Anticancer Drug Des (2001) 16(2/3):155-166.
10. Hood KA, West LM, Rouwé B, Northcote PT, Berridge MV, Wakefield St J, Miller JH: Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res (2002) 62(12):3356-3360.
11. Gaitanos TN, Buey RM, Díaz JF, Northcote PT, Teesdale-Spittle P, Andreu JM, Miller JH: Peloruside A does not bind to the taxoid site on β-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res (2004) 64(15):5063-5067. • Demonstrates the activity of peloruside A in multidrug-resistant cells.
12. Wilmes A, Bargh K, Kelly C, Northcote PT, Miller JH: Peloruside A synergizes with other microtubule-stabilizing agents in cultured cancer cell lines. Mol Pharmaceutics (2007) 4(2):269-280. • Highlights the complexity of drug interactions leading to synergies of agents, which inhibit cell proliferation.
13. Crimmins MT: Synthetic approaches to the microtubule stabilizing agent (-)-laulimalide. Curr Opin Drug Discovery Dev (2002) 5(6):944-959.
14. Hamel E, Day BW, Miller JH, Jung MK, Northcote PT, Ghosh AK, Curran DP, Cushman M, Nicolaou KC, Paterson I, Sorensen EJ: Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol (2006) 70(5):1555-1564. • Describes the synergistic effects and receptor site identification of peloruside A.
15. Pineda O, Farràs J, Maccari L, Manetti F, Botta M, Vilarrasa J: Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicines. Biorg Med Chem Lett (2004) 14(19):4825-4829. • Describes the modeling of a pharmacophore concept.
16. Miller JH, Rouwé B, Gaitanos TN, Hood KA, Crume KP, Bäckström BT, La Flamme AC, Berridge MV, Northcote PT: Peloruside A enhances apoptosis in H-ras-transformed cells and is cytotoxic to proliferating T-cells. Apoptosis (2004) 9(6):785-796. •• Describes an important investigation of the mechanism of action of peloruside A.
17. Ding AH, Porteu F, Sanchez E, Nathan CF: Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science (1990) 248(4953):370-372.
18. Bixby J, Ray TD, Chan FK-M: TNF, cell death and inflammation. Curr Med Chem - Antiinflamm Anti-Allergy Agents (2005) 4(6):557-567.
19. Hehlgans T, Pfeffer K: The intriguing biology of the tumor necrosis factor/tumor necrosis factor receptor superfamily: Players, rules and the games. Immunology (2005) 115(1):1-20.
20. Fitzpatrick FA, Wheeler R: The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents. Int Immunopharmacol (2003) 3(13-14):1699-1714.
21. Crume KP, Miller JH, La Flamme AC: Peloruside A, an antimitotic agent, specifically decreases tumor necrosis factor-α production by lipopolysaccharide-stimulated murine macrophages. Exp Biol Med (2007) 232(5):607-613.
22. Jiménez-Barbero J, Canales A, Northcote PT, Buey RM, Andreu JM, Díaz JF: NMR determination of the bioactive conformation of peloruside A bound to microtubules. J Am Chem Soc (2006) 128(27):8757- 8765. •• Describes a detailed study of the conformational analysis of peloruside A and the conformation of microtubule-bound substrates.
23. Liao X, Wu Y, De Brabander JK: Total synthesis and absolute configuration of the novel microtubule-stabilizing agent peloruside A. Angew Chem Int Ed (2003) 42(14):1648-1652. •• Describes the first total synthesis of (-)-peloruside A.
24. Corey EJ, Helal CJ: Reduction of carbonyl compounds with chiral oxazaborolidine catalysts: A new paradigm for enantioselective catalysis and a powerful new synthetic method. Angew Chem Int Ed (1998) 37(15):1986-2012.
25. Ramachandran PV: Pinane-based versatile 'allyl'boranes. Aldrichimica Acta (2002) 35(1):23-35.
26. Wender PA, De Brabander J, Harran PG, Jimenez J-M, Koehler MFT, Lippa B, Park C-M, Shiozaki M: Synthesis of the first members of a new class of biologically active bryostatin analogues. J Am Chem Soc (1998) 120(18):4534-4535.
27. Xu Z, Johannes CW, Houri AF, La DS, Cogan DA, Hofilena GE, Hoveyda AH: Applications of Zr-catalyzed carbomagnesation and Mocatalyzed macrocyclic ring closing metathesis in asymmetric synthesis. Enantioselective total synthesis of Sch-38516 (fluvirucin B1). J Am Chem Soc (1997) 119(43):10302-10316.
28. Grubbs RH: Olefin metathesis. Tetrahedron (2004) 60(34):7117-7140.
29. Taylor RE, Jin M: Toward a total synthesis of peloruside A: Enantioselective preparation of the C8-C19 region. Org Lett (2003) 5(26):4959-4961.
30. Jin M, Taylor RE: Total synthesis of (+)-peloruside A. Org Lett (2005) 7(7):1303-1305. •• Describes the first total synthesis of the natural antipode of peloruside A.
31. Paterson I, Di Francesco ME, Kühn T: Toward the synthesis of peloruside A: Fragment synthesis and coupling studies. Org Lett (2003) 5(4):599-602.
32. Cowden CJ, Paterson I: Asymmetric aldol reactions using boron enolates. Organic Reactions (1997) 51:1-200.
33. Zaitsev AB, Adolfsson H: Recent developments in asymmetric dihydroxylations. Synthesis (2006) (11):1725-1756.
34. Evans DA, Hoveyda AH: Samarium-catalyzed intramolecular Tishchenko reduction of β-hydroxy ketones. A stereoselective approach to the synthesis of differentiated anti-1,3-diol monoesters. J Am Chem Soc (1990) 112(17):6447-6449.
35. Ghosh AK, Kim JH: Synthetic studies of microtubule stabilizing agent peloruside A: An asymmetric synthesis of C10-C24 segment. Tetrahedron Lett (2003) 44(41):7659-7661.
36. Ghosh AK, Kim JH: An enantioselective synthesis of the C1-C9 segment of antitumor macrolide peloruside A. Tetrahedron Lett (2003) 44(20):3967-3969.
37. Liu B, Zhou W-S: Toward the total synthesis of natural peloruside A: Stereoselective synthesis of the backbone of the core. Org Lett (2004) 6(1):71-74.
38. Chen Z, Zhou W-S: A stereoselective synthesis of the C11-C19 fragment of (+)-peloruside A. Tetrahedron Lett (2006) 47(30):5289-5292.
39. Engers DW, Bassindale MJ, Pagenkopf BL: Synthesis of the C1-C12 segment of peloruside A by an α-benzyloxymethyl ketone aldol strategy. Org Lett (2004) 6(5):663-666.
40. Roulland E, Ermolenko MS: Synthesis of the C12-C19 fragment of (+)-peloruside A through a diastereomer-discriminating RCM reaction. Org Lett (2005) 7(11):2225-2228.
41. Kumar P, Naidu V, Gupta P: Application of hydrolytic kinetic resolution (HKR) in the synthesis of bioactive compounds. Tetrahedron (2007) 63(13):2745-2785.
42. Schrodi Y, Pederson RL: Evolution and applications of second-generation ruthenium olefin metathesis catalysts. Aldrichimica Acta (2007) 40(2):45-47.
43. -, TPAP: A catalytic oxidant for organic synthesis. Synthesis (1994) (7):639-666.
44. Stocker BL, Teesdale-Spittle P, Hoberg JO: Studies on the origin of 1,5-anti induction in boron-mediated aldol reactions. Eur J Org Chem (2004) (2):330-336.
45. List B, Lerner RA, Barbas CF III: Proline-catalyzed direct asymmetric aldol reactions. J Am Chem Soc (2000) 122(10):2395-2396.
46. List B, Pojarliev P, Castello C: Proline-catalyzed asymmetric aldol reactions between ketones and α-unsubstituted aldehydes. Org Lett (2001) 3(4):573-575.
47. Sakthivel K, Notz W, Bui T, Barbas CF III: Amino acid catalyzed direct asymmetric aldol reactions: A bioorganic approach to catalytic asymmetric carbon-carbon bond-forming reactions. J Am Chem Soc (2001) 123(22):5260-5267.
48. Gurjar MK, Pedduri Y, Ramana CV, Puranik VG, Gonnade RG: Toward a synthesis of the antitumor macrolide peloruside A: A chiral pool approach for the C1-C11 segment. Tetrahedron Lett (2004) 45(2):387-390.
49. Owen RM, Roush WR: Stereoselective synthesis of the C1-C11 fragment of peloruside A. Org Lett (2005) 7(18):3941-3944. • Describes a new double-allylation methodology for the efficient preparation of the C1-C11 subunit of peloruside A.
50. VICTORIA LINK LTD/NATIONAL INSTITUTE OF WATER AND ATMOSPHERIC RESEARCH (West LM, Northcote PT): Bioactive compound. WO-00110869 (2001).
51. BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (De Brabander J, Liao X): Synthesis of peloruside A and analogs thereof for use as antitumor agents. WO-2004074249 (2004).
52. THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Trojanowski JQ, Smith AB III, Lee VMY): Microtubule-stabilizing compounds and methods of their use. WO-2006091728 (2006).